Improved health outcomes with donepezil in moderate to severe Alzheimer's disease are associated with economic benefits

被引：0
|
作者：
Feldman, H
Gauthier, S
Hecker, J
Vellas, B
Hux, M
Emir, B
Subbiah, P
Mastey, V
机构：
[1] Pfizer Inc, New York, NY USA
[2] Innovus Res Inc, Burlington, ON, Canada
[3] Toulouse Univ, Alzheimers Ctr, Toulouse, France
[4] Repatriat Gen Hosp, Daw Pk, Australia
[5] McGill Ctr Studies Aging, Verdun, PQ, Canada
[6] UBC Hosp, Div Neurol, Vancouver, BC, Canada
来源：
NEUROBIOLOGY OF AGING | 2002年 / 23卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
285
引用
收藏
页码：S74 / S75
页数：2
相关论文
共 50 条
  • [31] Donepezil benefits patients with either mild or moderate Alzheimer's disease over one year
    Waldemar, G
    Winblad, B
    Engedal, K
    Soininen, HS
    Verhey, FRJ
    Wimo, A
    Wetterholm, AL
    Zhang, R
    Haglund, AÅ
    Subbiah, P
    [J]. NEUROLOGY, 2000, 54 (07) : A470 - A470
  • [32] Memantine/donepezil dual-therapy is superior to placebo/donepezil therapy for treatment of moderate to severe Alzheimer's disease
    Grossberg, G
    Tariot, P
    Farlow, M
    Gergel, I
    Graham, S
    Jin, J
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S393 - S393
  • [33] Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease
    Waldemar, G.
    Hyvarinen, M.
    Wetterberg, P.
    Korner, A.
    Lehto, H.
    Josiassen, M. K.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 : 188 - 188
  • [34] Memantine enhances autonomy in moderate to severe Alzheimer's disease patients already receiving donepezil
    Wirth, Y.
    Rive, B.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 474 - 474
  • [35] Donepezil versus vitamin E in Alzheimer's disease - Part 2: Mild versus moderate-severe Alzheimer's disease
    Onofrj, M
    Thomas, A
    Luciano, AL
    Iacono, D
    Di Rollo, A
    D'Andreamatteo, G
    Di Iorio, A
    [J]. CLINICAL NEUROPHARMACOLOGY, 2002, 25 (04) : 207 - 215
  • [36] Effects of donepezil in patients with moderate-to-severe Alzheimer's disease discontinuing memantine monotherapy
    Sakka, P.
    Tsolaki, M.
    Hort, J.
    Hager, K.
    Soininen, H.
    Lopez-Pousa, S.
    Li, C.
    Schwam, E.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 : 58 - 58
  • [37] Efficacy of donepezil on functional, behavioral, and cognitive symptoms in patients with moderate to severe Alzheimer's disease
    Gauthier, S
    Feldman, H
    Hecker, J
    Vellas, B
    Subbiah, P
    Whalen, E
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2000, 48 (08) : S2 - S2
  • [38] Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease
    Waldemar, Gunhild
    Hyvarinen, Maritta
    Josiassen, Mette Krog
    Korner, Alex
    Lehto, Heikki
    Wetterberg, Peter
    [J]. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2008, 23 (09) : 979 - 981
  • [39] Effect of memantine treatment at patients with moderate-severe Alzheimer's disease treated with Donepezil
    Szalontay, A. S.
    Chirita, R.
    Chirita, V.
    [J]. EUROPEAN PSYCHIATRY, 2008, 23 : S198 - S198
  • [40] Donepezil helps patients with severe Alzheimer"s disease
    Tanne, Janice Hopkins
    [J]. BRITISH MEDICAL JOURNAL, 2007, 335 (7613): : 226 - 226
12345